Quantitative determination of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in human plasma by GC-MS, RIA and HPLC.
Comparisons were made of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 levels in plasma determined by three assay methods. Plasma samples from Rhesus monkeys treated with 200 micrograms/kg 9-deoxo-16,16-dimethyl-9-methylene-PGE2 intravenously were analyzed by radioimmunoassay (RIA) and by high pressure liquid chromatography (HPLC). In a second experiment known amounts of 11 beta-3H-9-deoxo-16,16-dimethyl-9-methylene-PGE2 were added to human plasma at several concentration levels. The samples were analyzed by RIA, HPLC and gas chromatography-mass spectrometry (GC-MS). A limited number of comparisons have been made between RIA and GC-MS analysis of plasma samples from human subjects treated wtih 9-deoxo-16,16-dimethyl-9-methylene-PGE2. The results indicated that the three assay methods generally give comparable estimations of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 content in plasma.
D015064:16,16-Dimethylprostaglandin E2 / Q000031:analogs & derivatives / Q000097:blood*; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007700:Kinetics; D008253:Macaca mulatta; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000097:blood*; D011863:Radioimmunoassay
D011459:Prostaglandins E, Synthetic; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2